Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus reuteri ATCC PTA 5289
- Development stage
- Unknown
- Lead developer
- BioGaia
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus reuteri ATCC PTA 5289 is a probiotic bacterial strain developed and marketed by BioGaia AB. As a live biotherapeutic agent, it is primarily utilized in consumer health products targeting oral health, gut health, and immune support. The strain's mechanism of action involves the modulation of the local microbiota and the host's immune response. Specifically, it helps maintain a healthy balance in the oral cavity by displacing pathogenic bacteria and influencing inflammatory pathways. In clinical applications, it is frequently used in combination with another strain, L. reuteri DSM 17938, to treat conditions such as gingivitis, periodontitis, and oral mucositis. It is typically administered orally in the form of lozenges, tablets, or drops.
- Brand names
- BioGaia ProdentisGum PeriobalanceReladentReuterinOS
- Other names
- L. reuteri ATCC PTA 5289
Beyond the preview
Go deeper on Lactobacillus reuteri ATCC PTA 5289.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus reuteri ATCC PTA 5289.